Seer (NASDAQ:SEER) Announces Quarterly Earnings Results, Hits Estimates

Seer (NASDAQ:SEER) released its quarterly earnings results on Wednesday. The company reported ($0.30) EPS for the quarter, hitting the consensus estimate of ($0.30), FiscalAI reports. Seer had a negative return on equity of 25.81% and a negative net margin of 464.78%.The firm had revenue of $2.79 million for the quarter, compared to analyst estimates of $3.60 million.

Here are the key takeaways from Seer’s conference call:

• Seer reaffirmed its full-year 2026 revenue guidance of $16 million to $18 million, saying it still expects momentum to build through the year despite a soft first quarter and continued NIH funding pressure.
• Q1 revenue fell to $2.8 million from $4.2 million a year ago, reflecting weak academic/government funding, heavier competitive pressure, and some disruption from a commercial leadership transition.
• The company said its scientific validation continues to accelerate, with 84 peer-reviewed publications, preprints, and reviews now supporting the Proteograph platform, up sharply from 42 a year ago.
• Seer highlighted major progress in population-scale studies, including the PRECISE-SG100K biobank program and other large cohorts, which management believes could help drive broader adoption and larger future revenue opportunities.
• The company emphasized strong cost discipline, as operating expenses fell to $18.2 million from $22.8 million a year earlier, while it ended Q1 with $219.5 million in cash and investments and said it has enough liquidity to reach cash-flow breakeven.

Seer Stock Down 0.9%

Shares of SEER traded down $0.02 during trading on Friday, reaching $1.73. The company’s stock had a trading volume of 61,890 shares, compared to its average volume of 331,505. The company has a fifty day moving average of $1.81 and a two-hundred day moving average of $1.89. Seer has a twelve month low of $1.65 and a twelve month high of $2.41. The company has a market cap of $97.83 million, a price-to-earnings ratio of -1.40 and a beta of 1.63.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Canaccord Genuity Group assumed coverage on Seer in a research report on Monday, May 4th. They issued a “buy” rating and a $4.00 target price on the stock. TD Cowen raised Seer to a “strong-buy” rating in a research report on Monday, April 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Seer in a research report on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Seer presently has an average rating of “Buy” and a consensus price target of $4.00.

Institutional Investors Weigh In On Seer

Institutional investors have recently made changes to their positions in the company. Occudo Quantitative Strategies LP bought a new stake in shares of Seer in the 2nd quarter valued at approximately $25,000. Marshall Wace LLP bought a new stake in shares of Seer in the 4th quarter valued at approximately $85,000. Quadrature Capital Ltd bought a new stake in shares of Seer in the 4th quarter valued at approximately $101,000. Barclays PLC increased its holdings in shares of Seer by 685.0% in the 4th quarter. Barclays PLC now owns 60,717 shares of the company’s stock valued at $111,000 after acquiring an additional 52,982 shares during the last quarter. Finally, Corient Private Wealth LLC increased its holdings in shares of Seer by 46.3% in the 2nd quarter. Corient Private Wealth LLC now owns 63,200 shares of the company’s stock valued at $135,000 after acquiring an additional 20,000 shares during the last quarter. 75.20% of the stock is currently owned by institutional investors.

About Seer

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.